|
|
Company News
All Releases
 |
Achillion Announces Executive Promotion
Feb 3, 2012
|
9.0 KB |
|
| |
NEW HAVEN, Conn., Feb. 3, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the promotion of Mr. Joseph Truitt to Senior Vice President of Business Development. Mr. Truitt maintains his position...
|
|
Achillion to Present at the Noble Financial Capital Markets' Eighth Annual Equity Conference
Jan 13, 2012
|
8.1 KB |
|
| |
NEW HAVEN, Conn., Jan. 13, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Joseph Truitt, Senior Vice President of Business Development and Chief Commercial Officer of Achillion, will pre...
|
|
Achillion Reports Clinical Data on Portfolio of Protease Inhibitors
Jan 9, 2012
|
20.0 KB |
|
| |
Once-daily ACH-1625 safe, well-tolerated and achieves 100% cEVR after 12 weeks of treatmentPilot study of ACH-1625 in HCV genotype 3 achieves maximal 3.68 log10 reductionACH-2684 safe, well tolerated and achieves HCV genotype 1 maximal 4.63 log10 reduction; Additional dosing on-going
NEW HAVEN, Conn., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Achillion ...
|
|
ACH-1625 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
Jan 4, 2012
|
13.5 KB |
|
| |
NEW HAVEN, Conn., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACH-1625 for the treatmen...
|
|
Achillion Announces Preliminary Phase 1b Proof-of-Concept Data With ACH-2928 NS5A Inhibitor for the Treatment of Hepatitis C
Dec 5, 2011
|
13.8 KB |
|
| |
NEW HAVEN, Conn., Dec. 5, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported proof-of-concept data from its Phase 1b clinical trial of ACH-2928, a first-generation NS5A inhibitor, demonstrating th...
|
|
Achillion to Present at the 23rd Annual Piper Jaffray Health Care Conference
Nov 21, 2011
|
7.9 KB |
|
| |
NEW HAVEN, Conn., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that members of the Company's executive team will present at the upcoming 23rd Annual Piper Jaffray Health Care Confe...
|
|
Achillion Reports Third Quarter and Nine Month 2011 Financial Results
Nov 8, 2011
|
17.7 KB |
|
| |
NEW HAVEN, Conn., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and nine months ended September 30, 2011. For the third quarter of 2011, Achillion repo...
|
|
Achillion to Present at the Credit Suisse 2011 Healthcare Conference
Nov 3, 2011
|
7.9 KB |
|
| |
NEW HAVEN, Conn., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Dr. Milind Deshpande, President of Research and Development and Chief Scientific Officer, will provide a corporat...
|
|
Achillion Announces Nomination of Second Generation NS5A Inhibitor for the Treatment of Hepatitis C
Oct 13, 2011
|
11.2 KB |
|
| |
NEW HAVEN, Conn., Oct. 13, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the nomination of an additional clinical candidate for the treatment of the hepatitis C virus (HCV) from its NS5A inh...
|
|
Achillion to Present Updated Clinical and Preclinical Data on Multiple Compounds at AASLD 2011
Oct 3, 2011
|
11.8 KB |
|
| |
NEW HAVEN, Conn., Oct. 3, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that four abstracts on HCV compounds discovered and developed by Achillion were accepted for presentation at the 62nd ...
|
|
Achillion to Present at the JMP Healthcare Conference
Sep 22, 2011
|
8.1 KB |
|
| |
NEW HAVEN, Conn., Sept. 22, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will provide a corporate update at the upcoming Si...
|
|
Achillion to Present at Two Upcoming Investor Conferences
Aug 31, 2011
|
8.9 KB |
|
| |
NEW HAVEN, Conn., Aug. 31, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that members of the executive team will present at the following upcoming investor conferences:
Stifel Nicholas ...
|
|
Achillion Reports Second Quarter and Six Month 2011 Financial Results
Aug 8, 2011
|
18.1 KB |
|
| |
NEW HAVEN, Conn., Aug. 8, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and six months ended June 30, 2011. For the second quarter of 2011, Achillion reported ...
|
|
Achillion to Host Conference Call to Discuss Second Quarter Financial Results and Upcoming Milestones
Aug 2, 2011
|
9.3 KB |
|
| |
NEW HAVEN, Conn., Aug. 2, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, will release second quarter 2011 financial results on Monday, August 8, 2011 after the U.S. financial markets close. Achillion executi...
|
|
Achillion Announces Executive Promotion
Jul 26, 2011
|
9.5 KB |
|
| |
NEW HAVEN, Conn., July 26, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the promotion of Dr. Elizabeth A. Olek to Senior Vice President of Clinical Development and maintains her position as...
|
|
Achillion Announces Initiation of Phase 1 Trial of ACH-2928 for the Treatment of Hepatitis C
Jul 11, 2011
|
11.7 KB |
|
| |
NEW HAVEN, Conn., July 11, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has begun dosing in a Phase 1 clinical trial of ACH-2928, a NS5A inhibitor, being developed for the treatment...
|
|
Achillion Pharmaceuticals Announces Closing of Public Offering and Exercise of Overallotment Option
Jun 27, 2011
|
9.5 KB |
|
| |
NEW HAVEN, Conn., June 27, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that the underwriters exercised their option to purchase an additional 1,440,000 shares from Achillion in its previously announced underwritten public offering of common stock at a price to the public of $5.90 per share. The offering of...
|
|
Achillion Initiates 12-Week Dosing in Phase 2 Trial of ACH-1625 for the Treatment of Chronic Hepatitis C
Jun 22, 2011
|
12.1 KB |
|
| |
NEW HAVEN, Conn., June 22, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the Company has initiated patient dosing in segment 2 of its Phase 2 clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) for genotype 1 treatment naïve HCV-infected patients. ACH-1625, discovered and advanc...
|
|
Achillion Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Jun 22, 2011
|
9.7 KB |
|
| |
NEW HAVEN, Conn., June 22, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the pricing of an underwritten public offering of 9,600,000 shares of its common stock at a price to the public of $5.90 per share. The net proceeds to Achillion from the sale of the shares, after deducting underwriting discounts and co...
|
|
Achillion Pharmaceuticals Announces Proposed Public Offering of Common Stock
Jun 20, 2011
|
9.7 KB |
|
| |
NEW HAVEN, Conn., June 20, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that it has commenced an underwritten public offering of an aggregate of 9,000,000 shares of its common stock. In connection with this offering, Achillion plans to grant the underwriters a 30-day option to purchase up to an additional 1...
|
|
|
= add file to Briefcase
|
